Preferred Label : Cabozantinib;
NCIt synonyms : N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-
fluorophenyl)-; XL184;
NCIt definition : An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with
potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several
RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte
growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial
growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem
cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine
kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result
in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor
regression.;
UNII : 1C39JW444G;
InChIKey : ONIQOQHATWINJY-UHFFFAOYSA-N;
CAS number : 849217-68-1;
Chemical formula : C28H24FN3O5;
Codes from synonyms : 82;
Origin ID : C52200;
UMLS CUI : C3181682;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
